Strober, B., Bachelez, H., Crowley, J., Elewski, B. E., Gooderham, M., Menter, A., . . . Armstrong, A. (2024). Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial). Wiley. https://doi.org/10.1111/jdv.19748
Citazione stile Chigago Style (17a edizione)Strober, Bruce, et al. Efficacy of Long‐term Risankizumab Treatment for Moderate‐to‐severe Plaque Psoriasis: Subgroup Analyses by Baseline Characteristics and Psoriatic Disease Manifestations Through 256 weeks (LIMMitless Trial). Wiley, 2024. https://doi.org/10.1111/jdv.19748.
Citatione MLA (9a ed.)Strober, Bruce, et al. Efficacy of Long‐term Risankizumab Treatment for Moderate‐to‐severe Plaque Psoriasis: Subgroup Analyses by Baseline Characteristics and Psoriatic Disease Manifestations Through 256 weeks (LIMMitless Trial). Wiley, 2024. https://doi.org/10.1111/jdv.19748.